Skip to main content

Moderna posts quarterly loss as company takes $1.3 billion write-down on unused Covid shots

Moderna's total revenue for the third quarter still topped Wall Street's expectations despite plummeting demand for its Covid-19 shot.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.